Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (21-30 of 101) with videos related to

Pageof 11
Sort By:
Human Immunology|November 24, 2004
Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cellsDelphine Rea, Drake Laface, Beth Hutchins, et al.
British Journal of Haematology|January 10, 2012
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutationMarie-Magdelaine Coude, Odile Luycx, Marie-Estelle Cariou, et al.
Bulletin Du Cancer|October 3, 2008
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]Pascale Cony-Makhoul, Anne Bergeron, Sélim Corm, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid LeukemiaEmmanuelle Vidal-Petiot, Delphine Rea, Fidéline Serrano, et al.
Leukemia Research|March 10, 2021
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE studyGabriel Etienne, Delphine Rea, Valerie Coiteux, et al.
Journal of the National Cancer Institute|August 5, 2011
Severe peripheral arterial disease during nilotinib therapyPhilipp Le Coutre, Delphine Rea, Elisabetta Abruzzese, et al.
European Journal of Haematology|May 6, 2015
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapyThomas Cluzeau, Eric Lippert, Jean-Michel Cayuela, et al.
Journal of Medical Economics|July 11, 2023
Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinibJorge E Cortes, Delphine Rea, Michael J Mauro, et al.
JAAD Case Reports|November 21, 2018
Eruptive melanocytic nevi associated with ponatinibInès Devred, Jean-Philippe Arnault, Alanoud Adas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communicationLaurence Legros, Nathalie Ebran, Emmanuelle Stebe, et al.
Pageof 11

Showing results (21-30 of 101) with videos related to

Sort By:
Pageof 11
Human Immunology|November 24, 2004
Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cellsDelphine Rea, Drake Laface, Beth Hutchins, et al.
British Journal of Haematology|January 10, 2012
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutationMarie-Magdelaine Coude, Odile Luycx, Marie-Estelle Cariou, et al.
Bulletin Du Cancer|October 3, 2008
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]Pascale Cony-Makhoul, Anne Bergeron, Sélim Corm, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid LeukemiaEmmanuelle Vidal-Petiot, Delphine Rea, Fidéline Serrano, et al.
Leukemia Research|March 10, 2021
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE studyGabriel Etienne, Delphine Rea, Valerie Coiteux, et al.
Journal of the National Cancer Institute|August 5, 2011
Severe peripheral arterial disease during nilotinib therapyPhilipp Le Coutre, Delphine Rea, Elisabetta Abruzzese, et al.
European Journal of Haematology|May 6, 2015
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapyThomas Cluzeau, Eric Lippert, Jean-Michel Cayuela, et al.
Journal of Medical Economics|July 11, 2023
Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinibJorge E Cortes, Delphine Rea, Michael J Mauro, et al.
JAAD Case Reports|November 21, 2018
Eruptive melanocytic nevi associated with ponatinibInès Devred, Jean-Philippe Arnault, Alanoud Adas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communicationLaurence Legros, Nathalie Ebran, Emmanuelle Stebe, et al.
Pageof 11